Infliximab is a medication used to treat autoimmune diseases like rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, etc. It works by targeting and neutralizing tumor necrosis factor-alpha (TNF-α), a protein involved in inflammation.
Sometimes, patients treated with infliximab can develop antibodies against the drug. These antibodies can reduce the effectiveness of infliximab by neutralizing its action or causing allergic reactions. When antibodies develop, they may decrease drug levels in the bloodstream and cause a loss of response to treatment over time. This phenomenon is known as immunogenicity.
To manage this issue, one may need to adjust the dosage or frequency of infliximab, switch to a different medication, or use combination therapy with immunosuppressants to reduce the likelihood of antibody formation. Additionally, newer formulations of biologic drugs like infliximab have been developed to minimize immunogenicity and prolong effectiveness.
Regular monitoring of drug levels and antibodies is recommended for patients receiving infliximab therapy.
See also Infliximab
